Morgan Stanley enters its May 14 earnings week with a clear theme: insiders are selling into strength while the Street broadly cheered last month's results.
The most striking signal of the past three weeks has been sustained insider selling at the senior-most level. Co-Presidents Andy Saperstein and Daniel Simkowitz, along with Chief Legal Officer Eric Grossman and Executive VP Mandell Crawley, all unloaded shares between April 16 and April 20. Saperstein alone sold more than $9.4m worth across multiple tranches at prices from $187 to $191. The cluster of sales landed immediately after the Q1 earnings beat on April 15 — a textbook post-earnings-window distribution. Net insider activity over the past 90 days still shows a positive net share count of around 225,000 shares, but that reflects earlier option conversions, not fresh conviction buying. The message from the executive suite is not panic — but it is not accumulation either.
Short positioning tells a very relaxed story. SI fell another 1.7% on the week to roughly 0.95% of free float — a level so modest it barely registers as a headwind. The ORTEX short score is a muted 29.8, and it has drifted lower all week. Borrow conditions remain almost frictionless: cost to borrow ticked up to 0.40% annualised, a 30-day high but still among the cheapest borrows in the market. Availability is wide, with no signs of any squeeze pressure building in the lending pool. Short sellers are not a meaningful force here.
Options positioning is the more nuanced read. The put/call ratio nudged to 1.46, sitting above its 20-day average of 1.41 by roughly 1.4 standard deviations — not an extreme, but a gentle lean toward downside protection heading into the May 14 print. The ratio has crept up every day this week from 1.40 on May 1. At 1.46, it remains well below the 52-week high of 1.62 touched earlier this year, so this is caution, not alarm. The options market appears to be covering routine tail risk ahead of results rather than pricing in a specific negative catalyst.
The Street turned constructively bullish in the wake of Q1. After a 16% revenue jump year-on-year to $20.5bn and a 20% return on equity, nearly every firm that updated its view on April 16 raised its price target. Barclays went to $230, BofA Securities to $225, KBW to $218, and Goldman Sachs to $205 — the Goldman move especially notable given the Neutral rating it kept. The consensus mean target of $202 sits roughly 7% above Wednesday's close of $189.25. Wells Fargo's Mike Mayo, maintaining Equal-Weight, raised his target to $200 — essentially ratifying the stock as fairly valued at current levels. The bull case centres on the 30% pre-tax margin in Wealth Management and a capital return stance that could approach 100% of earnings. Bears point to pressure in asset management and lingering capital markets sensitivity. A trailing P/E near 15.6x and a price-to-book of 2.67x represent a meaningful re-rating — both multiples expanded roughly 9% over the past 30 days as the stock put on 14%.
The May 14 Q2 earnings event is now the cleanest focus. The last two prints produced day-one gains of 2.2% and 4.6% respectively, and five-day drifts of 4.2% and 1.3% in the same direction. Closest peer GS edged up 1.7% on Tuesday while EVR rose 2.3%. Both finished the week lower, suggesting sector-wide caution rather than MS-specific positioning. T. Rowe Price added 3.4m shares in the most recent quarter, the largest institutional build among disclosed movers — a signal that at least one patient money manager views the re-rating as incomplete.
What to watch: whether the put/call ratio continues to drift toward its 52-week peak in the days ahead of the May 14 print, and whether the insider selling pace persists or pauses — two barometers that will frame how much of the analyst optimism is actually translating into positioning.
See the live data behind this article on ORTEX.
Open MS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
